Recursion appoints CMO David Mauro; completes Valence acquisition for up to ~8.1M shares

RECURSION PHARMACEUTICALS, INC.

David Mauro appointed CMO effective June 1; brings 20+ years oncology drug development experience from Codiak, Checkmate, Prelude, Advaxis.
Acquisition of Valence Discovery completed; consideration includes up to ~2.2M Class A shares and ~5.9M exchangeable shares.
Recursion assumes Valence options exercisable for up to ~0.8M Class A shares; total potential dilution up to ~8.9M shares.
Dr. Mauro will lead Recursion's five clinical programs and growing pre-clinical pipeline.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Shafique Virani

Interim Chief Medical Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2023-06-01
Successor: David Mauro
Filed: May 17, 2023, 7:59 PM ET

Shafique Virani, M.D., who has been serving in the role of Chief Corporate Development Officer and Interim Chief Medical Officer, will no longer hold the position of Interim Chief Medical Officer, effective June 1, 2023, but will continue serving in the role of Chief Corporate Development Officer.

Appointed

David Mauro

Chief Medical Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2023-06-01
Filed: May 17, 2023, 7:59 PM ET

On May 16, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) announced that it has appointed David Mauro, M.D., Ph.D., to the position of Chief Medical Officer, effective June 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shafique Virani changed role as Interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..

Action: will no longer hold
Role: Interim Chief Medical Officer

Exact text from the filing

Shafique Virani, M.D., who has been serving in the role of Chief Corporate Development Officer and Interim Chief Medical Officer, will no longer hold the position of Interim Chief Medical Officer, effective June 1, 2023, but will continue serving in the role of Chief Corporate Development Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Mauro was appointed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On May 16, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) announced that it has appointed David Mauro, M.D., Ph.D., to the position of Chief Medical Officer, effective June 1, 2023.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.